Curtis Dobrowolski, PhDCo-Founder at Nava Therapeutics
Curtis Dobrowolski graduated with a bachelors of science in biology from Jacksonville University in 2008 followed by a masters in Infectious disease and Immunology at the University of Sydney in 2010. In 2018 he completed his Ph.D. in molecular virology at Case Western Reserve University focusing on the reversal of HIV latency. Curtis then joined the James Dahlman lab at the Georgia Institute of Technology in 2019 as a postdoc to help develop a viral delivery system using lipid nanoparticles. With his extensive scRNA-sequencing experience he was able to create a high throughput LNP screening platform called SENT-seq. This technology was spun out into Nava Therapeutics, which utilizes high throughput screening of Lipid Nanoparticles in vivo using single cell RNA sequencing as our final readout.
Identifying novel LNPs by Combining High Throughput Screening and Single Cell Multiomic Readouts, 11:45amView Session